window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 25, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

biopharma R&D

  • Digital & Data,Drug Discovery & Development,Manufacturing & Supply Chain

    Sapio Sciences and ZS partner on biopharma laboratory digitalisation

    Sapio Sciences has partnered with consulting and technology firm ZS [...]

    June 9, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development

    Research finds scientists view ELNs as ‘glorified filing cabinets’, driving duplication and shadow AI use

    A new survey by Sapio Sciences has found widespread frustration [...]

    May 5, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development

    Sapio Sciences appoints Rich Roda as chief financial officer

    Sapio Sciences has appointed Rich Roda as chief financial officer, [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Bionyra launches with $165M Series A to advance immunology biologics pipeline
    Categories: Biotech & Pharma Business, Drug Discovery & Development, Pharmaceuticals and therapeutics
  • Atsena advances gene therapy ATSN-201 into Phase 3 trial for inherited blindness
    Categories: Advanced Therapies, Clinical & Regulatory, Genomics and sequencing, Therapeutic Areas
  • Pierre Fabre wins EU approval for first-line BRAFTOVI regimen in BRAF-mutant colorectal cancer
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top